⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3417508 | 0.72 | ALDH1A1 (0.36) | — | |
| SCHEMBL31301182 | 0.72 | CCR1 (0.64) | — | |
| SCHEMBL8193 | 0.72 | CCR1 (0.55) | — | |
| SCHEMBL28304525 | 0.72 | CCR1 (0.55) | — | |
| SCHEMBL29354893 | 0.72 | CCR1 (0.55) | — | |
| Cyclohexane SCHEMBL28067655 | 0.70 | ALDH1A1 (0.48) | — | |
| Hydrochloric Acid SCHEMBL3710471 | 0.69 | CCR1 (0.52) | — | |
| Ammonia Solution, Strong SCHEMBL2732606 | 0.69 | CCR1 (0.52) | — | |
| Water SCHEMBL8327751 | 0.69 | CCR1 (0.52) | — | |
| Hydrochloric Acid SCHEMBL16337846 | 0.69 | CCR1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20220064197-A1 | PHOSPHINE OXIDE GROUP-CONTAINED TRANSITION METAL COMPLEX, AND POLYMER, MIXTURE, COMPOSITION, AND ORGANIC ELECTRONIC DEVICE THEREOF | GUANGZHOU CHINARAY OPTOELECTRONIC MATERIALS LTD. (CN) | 2022-03-03 | — | — | US | disclosed |
| US-11197857-B2 | Combination therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-11185531-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210106580-A1 | COMBINATION THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-15 | — | — | US | disclosed |
| US-20210078951-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2021-03-18 | — | — | US | disclosed |
| US-10800743-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-2970132-B1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200289469-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-8299262-B2 | Pyridylmethyl-sulfonamide compounds | BASF SE (DE) | 2012-10-30 | — | — | US | disclosed |
| WO-2010139653-A1 | FUNGICIDAL MIXTURES COMPRISING HETERAROMATIC SULFONAMIDES | BASF SE (DE) | 2010-12-09 | — | — | WO | disclosed |
| US-20100249077-A1 | Pyridylmethyl-Sulfonamide Compounds | BASF SE (DE) | 2010-09-30 | — | — | US | disclosed |
| EP-2231605-A1 | PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009071448-A1 | PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071449-A1 | PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2009-06-11 | — | — | WO | disclosed |
| US-7176215-B2 | Bicyclic oxopyridine and oxopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2007-02-13 | — | — | US | disclosed |
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | UCB PHARMA S.A. (BE) | 2004-12-16 | — | — | US | disclosed |
| EP-1438313-A1 | BICYCLIC OXOPYRIDINE AND OXOPYRIMIDINE DERIVATIVES | Celltech R & D Limited (GB) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003033502-A1 | BICYCLIC OXOPYRIDINE AND OXOPYRIMIDINE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |